Objective: To review the pharmacology, efficacy, and safety of apremilast and determine its
role relative to other agents in the treatment of psoriasis and psoriatic arthritis. Data Sources …

Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …

Objective To evaluate the efficacy and safety of apremilast, a novel, orally available small
molecule that specifically targets phosphodiesterase 4, in the treatment of active psoriatic …

Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …

Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints that occurs in patients
with psoriasis. The spectrum of PsA includes arthritis, dactylitis, enthesitis, axial involvement …

Introduction: Psoriasis is a common skin disorder characterized by chronic inflammatory
lesions that are frequently vexing for patients and difficult for physicians to treat. Although …

The FDA has given approval for the use of apremilast in adults with active psoriatic arthritis—
welcome news for patients and the rheumatology community. This commentary reviews …

Objective. To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4
inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior …

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation
of the immune system and release of pro-inflammatory mediators. Drugs available for …